Tags

Type your tag names separated by a space and hit enter

Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
Anticancer Res. 1996 Nov-Dec; 16(6B):3833-8.AR

Abstract

UGP, the beta-core fragment of human chorionic gonadotropin has been proposed as a tumor marker for gynecological malignancies. This fragment may be detected in a single morning-specimen of urine using an enzyme immunoassay. In this study, the diagnostic usefulness of urine UGP and serum CA 125 measurement for gynecological neoplasias (149 cases) was evaluated using a control group of patients with benign gynecological diseases (69 cases) and healthy females (99 cases). Considering the neoplastic patients in comparison to patients with benign diseases, the best diagnostic efficiency (78%) was found to correspond to a cut-off level of 120 pmol/mol creatinine the sensitivity being 73% and the specificity 90%. With this cut-off, an efficiency of 82% for healthy controls was obtained. Since the menopausal condition increases UGP levels, and though no significant difference for UGP was found between healthy subjects and patients with benign diseases, we decided to consider the reference populations as a single group. Thus, we evaluated the UGP performance on the basis of menopausal status. When a specificity of 95% was fixed, the cut-off values were 120 and 180 pmol/mol creatinine for pre- and postmenopausal women respectively, the sensitivity being 73% and 64%. Finally the combined evaluation of UGP and CA 125 improved their individual clinical efficiency for the diagnosis of ovarian serous cystadenocarcinomas, assuring a sensitivity of 86% and a specificity of 89%.

Authors+Show Affiliations

Department of Laboratory Medicine, University-Hospital of Padova, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9042266

Citation

Plebani, M, et al. "Combined Use of Urinary UGP and Serum CA 125 in the Diagnosis of Gynecological Cancers." Anticancer Research, vol. 16, no. 6B, 1996, pp. 3833-8.
Plebani M, Navaglia F, Basso D, et al. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. Anticancer Res. 1996;16(6B):3833-8.
Plebani, M., Navaglia, F., Basso, D., De Paoli, M., Nicoletto, M. O., Maraglino, E., & Torre, G. C. (1996). Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. Anticancer Research, 16(6B), 3833-8.
Plebani M, et al. Combined Use of Urinary UGP and Serum CA 125 in the Diagnosis of Gynecological Cancers. Anticancer Res. 1996 Nov-Dec;16(6B):3833-8. PubMed PMID: 9042266.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. AU - Plebani,M, AU - Navaglia,F, AU - Basso,D, AU - De Paoli,M, AU - Nicoletto,M O, AU - Maraglino,E, AU - Torre,G C, PY - 1996/11/1/pubmed PY - 1996/11/1/medline PY - 1996/11/1/entrez SP - 3833 EP - 8 JF - Anticancer research JO - Anticancer Res VL - 16 IS - 6B N2 - UGP, the beta-core fragment of human chorionic gonadotropin has been proposed as a tumor marker for gynecological malignancies. This fragment may be detected in a single morning-specimen of urine using an enzyme immunoassay. In this study, the diagnostic usefulness of urine UGP and serum CA 125 measurement for gynecological neoplasias (149 cases) was evaluated using a control group of patients with benign gynecological diseases (69 cases) and healthy females (99 cases). Considering the neoplastic patients in comparison to patients with benign diseases, the best diagnostic efficiency (78%) was found to correspond to a cut-off level of 120 pmol/mol creatinine the sensitivity being 73% and the specificity 90%. With this cut-off, an efficiency of 82% for healthy controls was obtained. Since the menopausal condition increases UGP levels, and though no significant difference for UGP was found between healthy subjects and patients with benign diseases, we decided to consider the reference populations as a single group. Thus, we evaluated the UGP performance on the basis of menopausal status. When a specificity of 95% was fixed, the cut-off values were 120 and 180 pmol/mol creatinine for pre- and postmenopausal women respectively, the sensitivity being 73% and 64%. Finally the combined evaluation of UGP and CA 125 improved their individual clinical efficiency for the diagnosis of ovarian serous cystadenocarcinomas, assuring a sensitivity of 86% and a specificity of 89%. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/9042266/Combined_use_of_urinary_UGP_and_serum_CA_125_in_the_diagnosis_of_gynecological_cancers_ L2 - https://antibodies.cancer.gov/detail/CPTC-MUC16-1 DB - PRIME DP - Unbound Medicine ER -